Market Research Reports and Industry Reports

Global Pharma US & EU Outlook 2015 : First In- Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Strategy Diversification Divested: Productivity measurements, Divestment of non-core assets resulting in healthy Cash position- Will accelerate Next wave of targeted acquisition

In the recent years several new therapies have been approved in the area of diabetes (SGLT-2, GLP-1 agonists), Multiple Sclerosis, HCV, melanoma and breast cancer from major pharmaceutical companies. Many of them are expected to reach multibillion dollars peak sales in the near-term which is likely to compensate the patent expiry loss in top-line revenue. Novel mechanisms like anti-PD1, anti-PCSK9 and CDK inhibitors have also got exclusive attention by large cap Pharma companies. Most companies are in race to acquire assets in these hot therapy areas. Companies who already have these assets are investing heavily in clinical development programs. The interest in pursuing opportunities in Oncology therapy is unhindered for all major Pharma companies. Research investments in oncology likely to continue for several more years due to the significant unmet need exist in this area.

But for a few companies, patent expiry impact continues to haunt the top-line and they are finding it difficult to replace declining sales with Proprietary pipeline products. Beyond 2013, the impact of patent loss will further aggravate the revenue decline. They have chosen strategies of prioritization pipeline assets, cost efficiency measures, divestment of non-core assets which yield poor margins and increase focus on therapy areas where they have already proven its mettle. Increase in dividend payout and share repurchase are some near term measures where they are actively participating. Gain in financial strength through divestment of non-core assets (OTC, Animal Health, Consumer health, Diagnostics) will be utilized in pursuing opportunities in high margin therapy areas. At the same time it has becoming more difficult to find such lucrative assets because they are scarce and if available are trading at very high premium in speculation of getting acquired (ex. Roche-Alexion). Going forward, Economies of Scale will also play a major role in swapping the non-core business among major pharma including Vaccines, OTC and animal health to improve margins.

Global Pharma continues to remain attractive due to management efforts on the restructuring of entire business model, cost efficiency measures, de-consolidation, acquisition of high value targeted assets, share repurchase program and dividend policy.
~AstraZeneca : Table 1: Competitive Landscape of Biologics in Severe Asthma
~GlaxoSmithKline : Table 1: Bydureon, albiglutide & Victoza Clinical data comparison
~Merck : Table 1: Keytruda: List of on-going combination studies
Table 2: On-going Phase III clinical trials for HCV combo
Table 3: On-going clinical trials of Keytruda
Table 4: Competitive Landscape of Anti-PD1
~Merck KGaA : Table 1: Merck Serono PhII and PhIII pipeline assets
~Novartis : Table 1: Efficacy data of LCZ696 in PARADIGM-HF
Table 2: Competition in Acromegaly
Table 3: PASSPORT-Efficacy and Safety Comparison: SIGNIFOR LAR VS.
SANDOSTATIN LAR
Table 4: Select Late- & Mid-stage pipeline: Plaque Psoriasis
Table 5: PHIII Clinical Data on Plaque Psoriasis of marketed products
Table 6: Patent Expiry Impact Through 2019
Table 7: Sandoz Biosimilar Pipeline Status
~Novo Nordisk : Table 1: Clinical data comparison of weekly GLP-1 Vs Victoza
Table 2: Obesity - Efficacy data comparison vs. marketed drugs

List Of Tables

~Merck KGaA : Chart 1: Merck KGaA - Revenue Contribution By Strategic Divisions In 2013
Chart 2: Geographic contribution based on 2013 sales

List Of Figures

~AstraZeneca : Table 1: Competitive Landscape of Biologics in Severe Asthma
~GlaxoSmithKline : Table 1: Bydureon, albiglutide & Victoza Clinical data comparison
~Merck : Table 1: Keytruda: List of on-going combination studies
Table 2: On-going Phase III clinical trials for HCV combo
Table 3: On-going clinical trials of Keytruda
Table 4: Competitive Landscape of Anti-PD1
~Merck KGaA : Table 1: Merck Serono PhII and PhIII pipeline assets
~Novartis : Table 1: Efficacy data of LCZ696 in PARADIGM-HF
Table 2: Competition in Acromegaly
Table 3: PASSPORT-Efficacy and Safety Comparison: SIGNIFOR LAR VS.
SANDOSTATIN LAR
Table 4: Select Late- & Mid-stage pipeline: Plaque Psoriasis
Table 5: PHIII Clinical Data on Plaque Psoriasis of marketed products
Table 6: Patent Expiry Impact Through 2019
Table 7: Sandoz Biosimilar Pipeline Status
~Novo Nordisk : Table 1: Clinical data comparison of weekly GLP-1 Vs Victoza
Table 2: Obesity - Efficacy data comparison vs. marketed drugs

Direct-Fed Microbials Market - Global Forecast to 2022

“Global direct-fed microbials market projected to have a CAGR of 6.96%.”The global direct-fed microbials market is projected to reach a value of USD 1,399.6 million by 2022, growing at a

USD 5650View Report

Brushless DC Motors Market - Global Forecasts to 2021

Brushless DC Motors Market by Type (Inner Rotor, and Outer Rotor), Speed (<500 RPM, 501 – 2000 RPM, 2001 – 10000 RPM, >10000 RPM), End User (Manufacturing, Medical Devices, Automotive,

USD 5650View Report

Smart Hospitality Market - Global Forecast to 2021

Smart Hospitality Market by Software (Hotel Operation Management System, Hotel Building Automation System), Service (Professional, Managed), Hotel Type (Business, Heritage & Boutique, Resorts & Spas), Deployment Model, and Region -

USD 5650View Report

Global Pharmaceutical Labeling Market Research Report 2017

Notes:Production, means the output of Pharmaceutical LabelingRevenue, means the sales value of Pharmaceutical LabelingThis report studies Pharmaceutical Labeling in Global market, especially in North America, Europe, China, Japan, Southeast Asia

USD 2900View Report

Global Pharmacy Automation Market Professional Survey Report 2017

Notes:Production, means the output of Pharmacy AutomationRevenue, means the sales value of Pharmacy AutomationThis report studies Pharmacy Automation in Global market, especially in North America, China, Europe, Southeast Asia, Japan

USD 3500View Report

Global Pharmacy Automation Systems Market Research Report 2017

Notes:Production, means the output of Pharmacy Automation SystemsRevenue, means the sales value of Pharmacy Automation SystemsThis report studies Pharmacy Automation Systems in Global market, especially in North America, Europe, China,

USD 2900View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 2000
  • Site Licence    $ 4000
  • Enterprisewide Licence    $ 6000
$ 2000

Reports Details

Published Date : Jan 2015
No. of Pages :63
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment